Identifying response and predictive biomarkers for Transcranial magnetic stimulation outcomes: protocol and rationale for a mechanistic study of functional neuroimaging and behavioral biomarkers in veterans with Pharmacoresistant depression
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: Although repetitive transcranial magnetic stimulation (‘TMS’) is becoming a gold standard treatment for pharmacoresistant depression, we lack neural target biomarkers for identifying who is most likely to respond to TMS and why. To address this gap in knowledge we evaluate neural targets defined by activation and functional connectivity of the dorsolateral prefrontal cortex-anchored cognitive control circuit, regions of the default mode network and attention circuit, and interactions with the subgenual anterior cingulate. We evaluate whether these targets and interactions between them change in a dose-dependent manner, whether changes in these neural targets correspond to changes in cognitive behavioral performance, and whether baseline and early change in neural target and cognitive behavioral performance predict subsequent symptom severity, suicidality, and quality of life outcomes. This study is designed as a pragmatic, mechanistic trial partnering with the National Clinical TMS Program of the Veteran’s Health Administration. Methods: Target enrollment consists of 100 veterans with pharmacoresistant Major Depressive Disorder (MDD). All veterans will receive a clinical course of TMS and will be assessed at ‘baseline’ pre-TMS commencement, ‘first week’ after initiation of TMS (targeting five sessions) and ‘post-treatment’ at the completion of TMS (targeting 30 sessions). Veterans will be assessed using functional magnetic resonance imaging (fMRI), a cognitive behavioral performance battery, and established questionnaires. Multivariate linear mixed models will be used to assess whether neural targets change with TMS as a function of dose (Aim 1), whether extent and change of neural target relates to and predicts extent of behavioral performance (Aim 3), and whether extent of neural target change predicts improvement in symptom severity, suicidality, and quality of life (Aim 3). For all three aims, we will also assess the contribution of baseline moderators such as biological sex and age. Discussion: To our knowledge, our study will be the first pragmatic, mechanistic observational trial to use fMRI imaging and cognitive-behavioral performance as biomarkers of TMS treatment response in pharmacoresistant MDD. The results of this trial will allow providers to select suitable candidates for TMS treatment and better predict treatment response by assessing circuit connectivity and cognitive-behavioral performance at baseline and during early treatment. Trial registration: ClinicalTrials.gov NCT04663481, December 5th, 2020, retrospectively registered. The first veteran was enrolled October 30th, 2020.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 2×
“Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.”
MethodMethods to detect, characterize, and remove motion artifact in resting state fMRI
Power, J. D., Mitra, A., Laumann, T. O., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.048 · Cited by 3,748
Skinner, H. A. (1982) · Addictive Behaviors · doi:10.1016/0306-4603(82)90005-3 · Cited by 3,134 · cited 1×
“Drug Use Disorders Identification Test (DUDIT): The DUDIT includes 11 questions that assess the presence of drug-related problems [34].”
MethodFunction in the human connectome: task-fMRI and individual differences in behavior
Barch, D. M., Burgess, G. C., Harms, M. P., Petersen, S. E., Schlaggar, B. L., Corbetta, M., Glasser, M. F., Curtiss, S., Dixit, S., Feldt, C., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.033 · Cited by 1,529 · cited 1×
“A visual summary of the GoNoGo paradigm [38] (left) and the N-Back working memory paradigm [39] (right)”
MethodDepression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“While definitions vary, pharmacoresistant or treatmentresistant depression is defined as lack of response to at least one antidepressant trial of adequate dose and duration [3]; up to 50% of MDD patients meet these criteria [4].”
BackgroundFox, M. D., Buckner, R. L., White, M. P., Greicius, M. D., & Pascual-Leone, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.028 · Cited by 1,270 · cited 3×
“, “anticorrelated”) DLPFC-sgACC resting state functional connectivity prior to DLPFC stimulation was associated with superior amelioration of clinical symptoms [18].”
BackgroundSheline, Y. I., Price, J. L., Yan, Z., & Mintun, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000446107 · Cited by 1,196
Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115 · cited 1×
“hypoactivation and connectivity involving the sgACC [16] in analyses of brain metabolism using positron”
MethodDepressive rumination, the default-mode network, and the dark matter of clinical neuroscience
Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.020 · Cited by 952 · cited 1×
“Some degree of DMN dysfunction is observed in persistently unwell MDD patients [13] and can identify MDD patients who do not remit on antidepressants [14].”
Background
Cited by
Madore, M. R., Kozel, F. A., Williams, L. M., Green, L. C., George, M. S., Holtzheimer, P. E., Yesavage, J. A., & Philip, N. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.025 · Cited by 50
Self-citationCortical excitability and the aging brain: toward a biomarker of cognitive resilience
Palermo, S., Di Fazio, C., Scaliti, E., Stanziano, M., Nigri, A., & Tamietto, M. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1542880 · Cited by 24
Philip, N. S., Ramanathan, D., Gamboa, B., Brennan, M. C., Kozel, F. A., Lazzeroni, L., & Madore, M. R. (2023) · Neuromodulation: Technology at the Neural Interface · doi:10.1016/j.neurom.2022.11.015 · Cited by 21
Self-citation
Metadata
- Authors
- Williams, L. M., Coman, J. T., Stetz, P. C., Walker, N. C., Kozel, F. A., George, M. S., Yoon, J., Hack, L. M., Madore, M. R., Lim, K. O., Philip, N. S., & Holtzheimer, P. E.
- Venue
- BMC Psychiatry
- Published
- 2021-01-13
- Volume
- 21
- Issue
- 1
- Pages
- 35-35
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W3121033762
- Cited by
- 50
- References
- 26
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identifying response and predictive biomarkers for Transcranial magnetic stimulation outcomes: protocol and rationale for a mechanistic study of functional neuroimaging and behavioral biomarkers in veterans with Pharmacoresistant depression. https://app.cochat.ai/papers/10.1186/s12888-020-03030-z
- The paper
- Williams, L. M., Coman, J. T., Stetz, P. C., Walker, N. C., Kozel, F. A., George, M. S., Yoon, J., Hack, L. M., Madore, M. R., Lim, K. O., Philip, N. S., & Holtzheimer, P. E. (2021). Identifying response and predictive biomarkers for Transcranial magnetic stimulation outcomes: protocol and rationale for a mechanistic study of functional neuroimaging and behavioral biomarkers in veterans with Pharmacoresistant depression. BMC Psychiatry. https://doi.org/10.1186/s12888-020-03030-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.